NANOSCOPE TECHNOLOGIES LLC
Arlington, TX · Medtech · Private
Virally delivered engineered mechanosensitive ion channel (EMC) for intraocular pressure modulation in glaucoma
nanoscopetech.com →- Grants
- $14M
- 18 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 7 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Ambient light activatable opsin based therapy for age-related macular degeneration | $224,925 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | $224,370 | |
| Federal grant | Department of Health and Human Services · Phase I · Ambient light activatable opsin based therapy for age-related macular degeneration | $259,925 | |
| Federal grant | Department of Health and Human Services · Phase I · Ambient light activatable opsin based therapy for age-related macular degeneration | $35,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient light activatable opsin based therapy for age-related macular degeneration | $1,031,182 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient Light Activatable Opsin Based Therapy For Age-related Macular Degeneration | $2,168,352 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient light activatable opsin based therapy for age-related macular degeneration | $109,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient light activatable opsin based therapy for age-related macular degeneration | $950,373 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient Light Activatable Opsin Based Therapy For Age-related Macular Degeneration | $77,597 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | $779,869 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | $2,114,715 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | $678,626 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient light activatable opsin based therapy for age-related macular degeneration | $749,517 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy | $656,220 | |
| Federal grant | Department of Health and Human Services · Phase II · Ambient light activatable opsin based therapy for age-related macular degeneration | $737,805 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | $716,879 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | $1,592,229 | |
| Federal grant | Department of Health and Human Services · Phase II · Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | $875,350 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1742 | MIVI Neuroscience, Inc. | — | $67M |
| 1743 | THEIA IMAGING LLC | — | $160K |
| 1744 | APOLLO ENDOSURGERY US INC | — | $176M |
| 1745 | NANOSCOPE TECHNOLOGIES LLC | — | — |
| 1746 | Moximed, Inc | — | $185M |
| 1747 | IGI TECHNOLOGIES, INC | — | — |
| 1748 | DAIGNOSTX L.L.C. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Three-Dimensional Image Guided Scanning Irradiation Device for Targeted Ablation, Stimulation, Manipulation, Molecular Delivery and Physiological Monitoringgranted
- Method, Compositions and Applications of Mechanosensitive Channelsapplication
- Method, Compositions And Applications Of Mechanosensitive Channels In Visual Disorders And Other Applications Thereofgranted
- Cancer Diagnosis by Refractive Index Multifractalitygranted
- Optogenetic Modulation By Multi-Characteristic Opsins For Vision Restoration and Other Applicationsgranted
- Device And Method For Optical Retinographygranted
- Method, Compositions And Device For Nano-enhanced Opto-chemical Trans-differentiation Of Cells And Tissuesgranted
- Equation Learning Neural Networks in Degrading Channels for Neural Machine Maintenance and Applications Thereofapplication
- Nano-Enhanced Optical Delivery of Exogenous Molecules to Cells and Tissuesgranted
- Cancer Diagnosis By Refractive Index Multifractalityapplication
- Methods, Compositions And Applications Of Mechanosensitive Channels In Visual Disorders And Other Applications Thereofapplication
- Equation learning neural networks in degrading channels for neural machine maintenance and applications thereofapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.